Ratan J, Rohatgi S, Gupta D K, Ratan S
Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India.
Tohoku J Exp Med. 1997 Jan;181(1):161-6. doi: 10.1620/tjem.181.161.
The authors have tried to examine the hepatoprotective and cholerectic action of a new indigenised drug, Livzon (Hind Chemicals Ltd., Kanpur, India) and compared its action to Decholin (casella-Riedel Pharma GmbH, Frankfurt, Germany), a known hepatoprotective and choleretic agent. Albino rats were chosen as the experimental animals. Obstructive jaundice was created by ligating the common bile ducts after taking liver biopsies. The animals were divided into three groups: (i) Control group-no drug was given, (ii) Livzon trial group, (iii) Decholin group. The animals were reoperated, liver biopsies were taken and histologically examined. The study confirmed the hepatoprotective and choleretic actions of Livzon and Decholin. However, Decholin was more of a choleretic, the Livzon was more hepatoprotective.
作者试图研究一种新的国产化药物利夫松（印度坎普尔的利夫松制药有限公司）的保肝和利胆作用，并将其作用与已知的保肝利胆药物德国法兰克福的卡塞拉-里德尔制药有限公司生产的去氢胆酸进行比较。选用白化大鼠作为实验动物。在进行肝脏活检后，通过结扎胆总管制造梗阻性黄疸。将动物分为三组：（i）对照组——未给予药物；（ii）利夫松试验组；（iii）去氢胆酸组。对动物再次进行手术，取肝脏活检并进行组织学检查。该研究证实了利夫松和去氢胆酸的保肝和利胆作用。然而，去氢胆酸更侧重于利胆，而利夫松更侧重于保肝。
